Drug Trial Radar · NCT06400459
IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jun 25, 2024
Primary completion
Oct 15, 2024
Study completion Oct 15, 2024
Sponsor
- Lead sponsor
- IVIEW Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.
Conditions
- Dry Eye Disease
Interventions
IVW-1001 Ophthalmic Eyelid Wipe 0.1%Drug
IVW-1001 Ophthalmic Eyelid Wipe 0.1%
IVW-1001 Ophthalmic Eyelid Wipe 0.2%Drug
IVW-1001 Ophthalmic Eyelid Wipe 0.2%
IVW-1001 PlaceboDrug
IVW-1001 Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Schirmer'sTime frame: 29 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Houston Eye Associates
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.